Poliomyelitis

• CLINICAL_TRIALS withdrawal · 2022-01-14
  Clinical Trial Update: Evaluation of the Immunogenicity and Safety of Concomitant Administration of Novel Oral Polio Type 2 Vaccine and Bivalent Oral Polio Vaccine [Phase 3]

  Phase 3 clinical trial evaluating concomitant administration of Novel Oral Polio Type 2 vaccine with a bivalent OPV has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2017-12-26
  Clinical Trial Update: Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants [Phase 3]

  Phase 3 trial evaluating immunogenicity and safety of Infanrix-IPV/Hib (DTPa-IPV/Hib) in healthy Indian infants has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2017-06-27
  Clinical Trial Update: A Study to Evaluate Immunogenicity of Various Schedules of Inactivated Polio Vaccine [Phase 3]

  A Phase 3 clinical trial evaluating immunogenicity of various schedules of an inactivated poliovirus vaccine has been withdrawn.

• EMA withdrawal · 2012-08-16
  EMA Withdrawn: Hexavac (purified diphtheria toxoid;purified tetanus toxoid;purified pertussis toxoid;purified pertussis filamentous haemagglutinin;hepatitis B surface antigen;Inactivated Type 1 Poliovirus (Mahoney);Inactivated Type 3 Poliovirus (Saukett);Haemophilus influenzae type b polysaccharide) — Sanofi Pasteur MSD, SNC

  The EMA has withdrawn Hexavac, a hexavalent combination vaccine, from the market. The decision was taken in 2012 and concerns multiple indic…